Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: A multicenter randomized placebo-controlled trial (EMA91 Trial)

Leukemia

Volumn 13, Issue 8, 1999, Pages 1214-1220

  Thomas, X ^a   Fenaux, P ^b   Dombret, H ^c   Delair, S ^d   Dreyfus, F ^e   Tilly, H ^f   Vekhoff, A ^g   Cony Makhoul, P ^h   Leblond, V ⁱ   Troussard, X ^j   Cordonnier, C ^k   De Revel, T ^l   Simon, M ^m   Nicolini, F ⁿ   Stoppa, A M ^o   Janvier, M ^p   Bordessoule, D ^q   Rousselot, P ^c   Ffrench, M ^a   Marie, J P ^g   Archimbaud, E ^a   more..

^a EDOUARD HERRIOT HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d Department of Hematology   (France)

^e Hôpital Cochin ^*  (France)

^f CENTRE HENRI BECQUEREL   (France)

^g HÔTEL DIEU   (France)

^h HAUT LÉVÊQUE HOSPITAL   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j CAEN UNIVERSITY HOSPITAL   (France)

^k HENRI MONDOR HOSPITAL   (France)

^l PERCY MILITARY HOSPITAL   (France)

^m CENTRE HOSPITALIER DE VALENCIENNES   (France)

ⁿ HÔPITAL MICHALLON   (France)

^o INSTITUT PAOLI CALMETTES   (France)

^p CENTRE RENÉ HUGUENIN   (France)

^q DUPUYTREN UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Acute myeloid leukemia; GM CSF; Prognosis; Relapse; Sequential chemotherapy

Indexed keywords

CYTARABINE; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BLOOD TOXICITY; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CELL CYCLE; CELL CYCLE S PHASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPHIL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOCYTE TRANSFUSION; VOMITING;

EID: 0032819748     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401474     Document Type: Article

References (51)

1. Champlin R, Gale RP. Acute myelogenous leukemia: recent advances in therapy. Blood 1987; 69: 1551-1562.
2. Vaughan WP, Karp JE, Burke PJ. Long chemotherapy-free remissions after single-cycle timed sequential chemotherapy for acute myelocytic leukemia. Cancer 1980; 45: 859-865.
3. Vaughan WP, Karp JE, Burke PJ. Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 1984; 64: 975-980.
4. Fiere D, Campos L, Vu Van H, Guyotat D, Archimbaud E, Extra JM, Coiffier B, Viala JJ, Bryon PA, Milan JJ, Ritouet D. Intensive timed chemotherapy protocol for 37 resistant or relapsing acute myeloid leukemias. Cancer Treat Rep 1986; 70: 285-286.
5. Archimbaud E, Leblond V, Michallet M, Cordonnier C, Fenaux P, Travade P, Dreyfus F, Jaubert J, Devaux Y, Fiere D. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for resistant or relapsing acute myelogenous leukemia. Blood 1991; 77: 1894-1900.
6. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade Ph, Troncy J, Assouline D, Fière D. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 1995; 13: 11-18.
7. Griffin JD, Young D, Hermann F, Wiper D, Wagner K, Sabbath KD. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 1986; 67: 1448-1453.
8. Hoang T, Nara N, Wong G, Clark SC, Minden MD, McCulloch EA. Effects of recombinant GM-CSF on the blast cells of acute myeloid leukemia. Blood 1986; 68: 313-316.
9. Vellenga E, Ostapovicz D, O'Rourke B, Griffin JD. Effects of recombinant IL-3, GM-CSF, and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. Leukemia 1987; 1: 584-589.
10. Delwel R, Salem M, Pellens K, Dorssers L, Wagemaker G, Clark S, Löwenberg B. Growth regulation of human acute myeloid leukemia: effect of five recombinant hematopoietic factors in a serum-free culture medium. Blood 1988; 72: 1944-1949.
11. Lista P, Brizzi MF, Avanzi G, Veglia F, Resegotti L, Pegoraro L. Induction of proliferation of acute myeloblastic leukemia (AML) cells with hemopoietic growth factors. Leukemia Res 1988; 12: 441-447.
12. Murohashi I, Nagata K, Suzuki T, Maruyama Y, Nara N. Effects of recombinant G-CSF and GM-CSF, on the growth in methyl-cellulose and suspension of the blast cells in acute myeloblastic leukemia. Leukemia Res 1988; 12: 433-440.
13. Budel LM, Touw IP, Delwel R, Clark SC, Löwenberg B. Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human myelocytic leukemia cells and relationship to the proliferative response. Blood 1989; 72: 565-571.
14. Onetto-Pothier N, Aumont N, Haman A, Bigras C, Wong GG, Clark SC, De Lean A, Hoang T. Characterization of granulocyte-macrophage colony-stimulating factor receptor on the blast cells of acute myeloblastic leukemia. Blood 1990; 75: 59-66.
15. Bhala K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Graham G. Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia 1988; 2: 810-813.
16. Miyauchi J, Kelleher CA, Wang C, Minkin S, McCulloch EA. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 1989; 73: 1272-1278.
17. Cannistra SA, Groshek P, Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989; 3: 328-334.
18. Butturini A, Santucci MA, Gale RP, Perocco P, Tura S. GM-CSF incubation prior to treatment with cytarabine or doxorubicin enhances drug activity against AML cells in vitro: a model for leukemia chemotherapy. Leukemia Res 1990; 14: 743-749.
19. Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990; 4: 826-834.
20. Estrov Z, Estey EH, Andreeff M, Talpaz M, Kurzrock R, Reading CL, Deisseroth AB, Gutterman JU. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. Exp Hematol 1992; 20: 558-564.
21. Teichmann JV, Ludwig WD, Thiel E. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells. Int J Hematol 1992; 55: 255-264.
22. Waga K, Furusawa S, Nagashima S, Saito K, Shishido H. Comparative effects of G-CSF, GM-CSF, and IL-3 on cytosine arabinoside-and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors. Int J Hematol 1992; 56: 17-27.
23. Norgaard JM, Langkjer ST, Ellegaard J, Palshof T, Clausen N, Hokland P. Synergistic and antagonistic effects of myeloid growth factors on in vitro cellular killing by cytotoxic drugs. Leukemia Res 1993; 17: 689-694.
24. Te Boekhorst PA, Löwenberg B, Sonneveld P. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia 1994; 8: 1180-1186.
25. Te Boekhorst PA, Löwenberg B, Vlastuin M, Sonneveld P. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL3 or GM-CSF stimulation. Leukemia 1993; 7: 1191-1198.
26. Van der Lely N, De Witte T, Wessels J, Raymakers R, Muus P, Preijers P. In vitro response of blasts to IL3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance ara-C cytotoxicity. Ann Hematol 1994; 68: 225-232.
27. Reuter C, Auf der Landwehr U, Schleyer E, Zuhlsdorf M, Ameling C, Rolf C, Wormann B, Büchner T, Hiddemann W. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor. Leukemia 1994; 8: 217-225.
28. Reuter C, Schleyer E, Rolf C, Wormann B, Büchner T, Hiddemann W. Differential effect of GM-CSF on intracellular ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts. Leukemia 1997; 11: 561-571.
29. Ben-Ishay Z, Prindull G, Sharon S. Improved prognosis in mice with advanced myeloid leukemia following administration of GM-CSF and cytosine arabinoside. Leukemia Res 1991; 15: 321-325.
30. Cannistra SA, DiCarlo J, Groshek P, Kanakura Y, Berg D, Mayer RJ, Griffin JD. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 1989; 5: 230-238.
31. Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Sillaber C, Haas O, Vieder L, Maurer D, Schulz G, Speiser W, Geissler K, Kier P, Hinterberger W, Lechner K. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991; 77: 700-711.
32. Löwenberg B, Boogaerts MA, Daenen SMGJ, Verhoef GEG, Hagenbeek A, Vellenga E, Ossenkoppele GJ, Huijgens PC, Verdonck LF, van der Lelie J, Wielenga JJ, Schouten HC, Gmür J, Gratwohl A, Hess U, Fey MF, van Putten WLJ. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997; 15: 3496-3506.
33. Karp JE, Donehower RC, Enterline JP, Dole GB, Fox MG, Burke PJ. In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood 1989; 73: 24-30.
34. Archimbaud E, Fenaux P, Reiffers J, Cordonnier C, Leblond V, Travade Ph, Troussard X, Tilly H, Auzanneau G, Marie JP, Berger E. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide and cytarabine for refractory acute myelogenous leukemia. Leukemia 1993; 7: 372-373.
35. Bennert JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 626-629.
36. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol 1991; 78: 325-329.
37. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Criteria for the diagnosis of acute leukemia of megacaryocyte lineage (M7). A report from the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 460-462.
38. World Health Organization Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication 48. WHO: Geneva, 1979.
39. Hiddemann W, Martin W-R, Sauerland C-M, Heinecke A, Büchner Th. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 1990; 4: 184-188.
40. Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussoff B, Silver RT, Karanas A, Cuttner J, Spurr CL, Hayes DM, Bloom J, Leone LA, Haurani F, Kyle R, Hutchison JL, Forcier RJ, Moon JH. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507-523.
41. Preisler HD. Failure of remission induction in acute myelocytic leukemia. Med Ped Oncol 1978; 4: 275-276.
42. Ffrench M, Magaud JP, Duhaut P, Bryon PA, Viala JJ. Determination of plasma cell labelling index with bromodeoxyuridine using a double immunoenzymatic technique. Stain Technol 1989; 65: 31-36.
43. Büchner T, Hiddeman W, Wörmann B, Rottman R, Zühlsdorf M, Maschmeyer G, Ludwig WD, Sauerland MC, Frisch J, Schulz G. GM-CSF multiple course priming and long-term administration in newly diagnosed AML. Hematologic and therapeutic effects. Blood 1994; 84(Suppl. 1): 27a.
44. Löwenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GEG, Vellenga E, Wijermans P, Berneman Z, Dekker AW, Stryckmans P, Schouten H, Jehn U, Muus P, Sonneveld P, Dardenne M, Zittoun R. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML11, a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 1997; 90: 2952-2961.
45. Heil G, Chadid L, Hoelzer D, Seipelt G, Mitrou P, Huber C, Kolbe K, Mertelsmann R, Lindemann A, Frisch J, Nicolay U, Gaus W, Heimel H. GM-CSF in a double-blind randomized, placebo-controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 1995; 9: 3-9.
46. Witz E, Sadoun A, Perrin MC, Berthou C, Brière J, Cahn JY, Lioure B, Witz B, François S, Desablens B, Pignon B, Le Prisé PY, Audhuy B, Caillot D, Casassus P, Delain M, Christian B, Tellier Z, Polin V, Hurteloup P, Harousseau JL. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 1998; 91: 2722-2730.
47. Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P, Hayat M, Peetermans M, Cadiou M, Solbu G, Petti MC, Willemze R. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996; 14: 2150-2159.
48. Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T, Ueda T, Minami S, Morishima Y, Saito Y, Furusawa S, Imai K, Takemoto Y, Miura Y, Teshima H, Hamajima N and the Kosheisho Leukemia Study Group. A double-blind study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994; 83: 2086-2092.
49. Estey E, Thall P, Kantarjian H, O'Brien S, Koller C, Freireich E, Keating M. Treatment of newly diagnosed AML with GM-CSF prior to and during chemotherapy: comparison to chemotherapy without GM-CSF. Blood 1991; 78 (Suppl. 1): 171a.
50. Gasson JC. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991; 77: 1131-1145.
51. Bhalla K, Holladay C, Arlin Z, Grant S, Ibrado AM, Jasiok M. Treatment with interkeukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of ara-C in vitro against acute myeloid leukemia blasts. Blood 1991; 78: 2674-2679.